Nasus Pharma Statistics

Total Valuation

Nasus Pharma has a market cap or net worth of $69.35 million. The enterprise value is $71.71 million.

Market Cap	69.35M
Enterprise Value	71.71M

Important Dates

The next estimated earnings date is Friday, March 20, 2026, before market open.

Earnings Date	Mar 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Nasus Pharma has 11.76 million shares outstanding. The number of shares has increased by 5.44% in one year.

Current Share Class	11.76M
Shares Outstanding	11.76M
Shares Change (YoY)	+5.44%
Shares Change (QoQ)	+2.75%
Owned by Insiders (%)	33.70%
Owned by Institutions (%)	4.91%
Float	6.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.06

Current Ratio	0.06
Quick Ratio	0.04
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-128.36

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-106.39%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	32.73%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$956,500
Employee Count	2
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	6.61
200-Day Moving Average	n/a
Relative Strength Index (RSI)	48.40
Average Volume (20 Days)	4,552

Short Selling Information

The latest short interest is 4,385, so 0.04% of the outstanding shares have been sold short.

Short Interest	4,385
Short Previous Month	5,300
Short % of Shares Out	0.04%
Short % of Float	0.07%
Short Ratio (days to cover)	0.65

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-1.41M
Pretax Income	-1.86M
Net Income	-1.91M
EBITDA	n/a
EBIT	-1.41M
Earnings Per Share (EPS)	-$0.26

Full Income Statement

Balance Sheet

The company has $203,000 in cash and $2.56 million in debt, with a net cash position of -$2.36 million or -$0.20 per share.

Cash & Cash Equivalents	203,000
Total Debt	2.56M
Net Cash	-2.36M
Net Cash Per Share	-$0.20
Equity (Book Value)	-4.31M
Book Value Per Share	-0.59
Working Capital	-4.66M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-918,000
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Nasus Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.44%
Shareholder Yield	n/a
Earnings Yield	-2.76%
FCF Yield	n/a

Analyst Forecast

The average price target for Nasus Pharma is $20.50, which is 247.46% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20.50
Price Target Difference	247.46%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1